About Us

Contact us
Community Advisory Board
Readers Rep
Careers
Events
Historical Archives
Recent Quotes
My Watchlist
Indicators
Local Stocks
San Diego Stocks
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by Pfizer Inc.

< Previous 1 2 3 4 5 6 7 8 9
...
12 13 Next >
News headline image
Pfizer to Showcase Scientific Advancements in Respiratory and Other Infectious Diseases at IDWeek 2024
From Pfizer Inc.
Via Business Wire
Tickers PFE
News headline image
Pfizer Voluntarily Withdraws All Lots of Sickle Cell Disease Treatment OXBRYTA® (voxelotor) From Worldwide Markets
From Pfizer Inc.
Via Business Wire
Tickers PFE
News headline image
Pfizer and BioNTech Receive Positive CHMP Opinion for Omicron KP.2-adapted COVID-19 Vaccine in the European Union
From Pfizer Inc.
Via Business Wire
Tickers BNTX PFE
News headline image
Pfizer Invites Public to View and Listen to Webcast of October 29 Conference Call with Analysts
From Pfizer Inc.
Via Business Wire
Tickers PFE
News headline image
Pfizer Presents Positive Data from Phase 2 Study of Ponsegromab in Patients with Cancer Cachexia
From Pfizer Inc.
Via Business Wire
Tickers PFE
News headline image
Pfizer’s BRAFTOVI® + MEKTOVI® Shows Long-Term Clinically Meaningful Response in Patients with BRAF V600E-Mutant Metastatic Non-Small Cell Lung Cancer
From Pfizer Inc.
Via Business Wire
Tickers PFE
News headline image
Pfizer Highlights Diverse Oncology Portfolio and Combination Approaches at ESMO 2024
From Pfizer Inc.
Via Business Wire
Tickers PFE
News headline image
Pfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conference
From Pfizer Inc.
Via Business Wire
Tickers PFE
News headline image
Pfizer Launches PfizerForAll™, a Digital Platform that Helps Simplify Access to Healthcare
From Pfizer Inc.
Via Business Wire
Tickers PFE
News headline image
Pfizer and BioNTech Receive U.S. FDA Approval & Authorization for Omicron KP.2-adapted COVID-19 Vaccine
From Pfizer Inc.
Via Business Wire
Tickers BNTX PFE
News headline image
Pfizer and BioNTech Provide Update on mRNA-based Combination Vaccine Program Against Influenza and COVID-19 in Individuals 18-64 Years of Age
From Pfizer Inc.
Via Business Wire
Tickers BNTX PFE
News headline image
Pfizer Announces Top-Line Results of ABRYSVO® for RSV in Immunocompromised Adults
From Pfizer Inc.
Via Business Wire
Tickers PFE
News headline image
Pfizer Reports Strong Second-Quarter 2024 Results And Raises 2024 Guidance
From Pfizer Inc.
Via Business Wire
Tickers PFE
News headline image
European Commission Approves Pfizer’s DURVEQTIX® (fidanacogene elaparvovec), a One-Time Gene Therapy for Adults with Hemophilia B
From Pfizer Inc.
Via Business Wire
Tickers PFE
News headline image
Pfizer Announces Positive Topline Results From Phase 3 Study of Hemophilia A Gene Therapy Candidate
From Pfizer Inc.
Via Business Wire
Tickers PFE
News headline image
Pfizer Advances Development of Once-Daily Formulation of Oral GLP-1 Receptor Agonist Danuglipron
From Pfizer Inc.
Via Business Wire
Tickers PFE
News headline image
Pfizer to Launch Process to Identify a Successor for Dr. Mikael Dolsten, Chief Scientific Officer and President, Pfizer Research & Development
From Pfizer Inc.
Via Business Wire
Tickers PFE
News headline image
Cyrus Taraporevala Elected to Pfizer’s Board of Directors
From Pfizer Inc.
Via Business Wire
Tickers PFE
News headline image
Pfizer and BioNTech Receive Positive CHMP Opinion for Omicron JN.1-adapted COVID-19 Vaccine in the European Union
From Pfizer Inc.
Via Business Wire
Tickers BNTX PFE
News headline image
Pfizer Declares Third-Quarter 2024 Dividend
From Pfizer Inc.
Via Business Wire
Tickers PFE
News headline image
Pfizer Invites Public to View and Listen to Webcast of July 30 Conference Call with Analysts
From Pfizer Inc.
Via Business Wire
Tickers PFE
News headline image
ELREXFIO™ Shows Median Overall Survival of More Than Two Years in People with Relapsed or Refractory Multiple Myeloma
From Pfizer Inc.
Via Business Wire
Tickers PFE
News headline image
Pfizer Provides Update on Phase 3 Study of Investigational Gene Therapy for Ambulatory Boys with Duchenne Muscular Dystrophy
From Pfizer Inc.
Via Business Wire
Tickers PFE
News headline image
Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference
From Pfizer Inc.
Via Business Wire
Tickers PFE
News headline image
Pfizer’s ADCETRIS® Regimen Produces Clinically Meaningful Improvement in Overall Survival in Patients with Relapsed/​Refractory Diffuse Large B-cell Lymphoma (DLBCL)
From Pfizer Inc.
Via Business Wire
Tickers PFE
News headline image
Pfizer’s LORBRENA® CROWN Study Shows Majority of Patients with ALK-Positive Advanced Lung Cancer Living Beyond Five Years Without Disease Progression
From Pfizer Inc.
Via Business Wire
Tickers PFE
News headline image
Pfizer Announces New Chief Strategy and Innovation Officer
From Pfizer Inc.
Via Business Wire
Tickers PFE
News headline image
Pfizer Reports First-Quarter 2024 Results
From Pfizer Inc.
Via Business Wire
Tickers PFE
News headline image
FDA Grants Full Approval for TIVDAK® to Treat Recurrent or Metastatic Cervical Cancer
From Pfizer Inc.
Via Business Wire
Tickers GMAB PFE
News headline image
Pfizer Highlights Progress in Accelerating Breakthrough Cancer Medicines at ASCO 2024 Annual Meeting
From Pfizer Inc.
Via Business Wire
Tickers PFE
< Previous 1 2 3 4 5 6 7 8 9
...
12 13 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.